Low molecular weight heparins could be important in cancer

BMJ 1999; 319 doi: https://doi.org/10.1136/bmj.319.7213.851 (Published 25 September 1999) Cite this as: BMJ 1999;319:851
  1. Sergio Siragusa, haematologist and angiologist (s.siragusa@smatteo.pv.it)
  1. Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico S Matteo, Pavia, Italy 27100

    EDITOR—Kakkar and Williamson clearly state the need for well conducted prospective clinical trials to evaluate the potential role of low molecular weight heparins in improving survival in cancer patients.1

    In the absence of properly designed trials, indirect data can be extrapolated from trials comparing low molecular weight heparins and unfractionated heparin in the treatment of venous thromboembolism. Reduced mortality in patients with venous thromboembolism who were treated with low molecular weight heparins seemed to be confined to patients with cancer.2 …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription